BOSTON SCIENTIFIC CORP

For the period ended Jun 30, 2025. Filed Aug 1, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 1, 2025

BSX$44.70+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations (Unaudited)

	Three Months EndedJune 30,		Six Months EndedJune 30,
(in millions, except per share data)	2025	2024	2025	2024
Net sales	$5,061	$4,120	$9,724	$7,977
Cost of products sold	1,637	1,270	3,090	2,479
Gross profit	3,424	2,850	6,633	5,498
Operating expenses:
Selling, general and administrative expenses	1,716	1,446	3,312	2,810
Research and development expenses	526	383	969	749
Royalty expense	14	9	28	19
Amortization expense	225	213	444	427
Intangible asset impairment charges	46	276	46	276
Contingent consideration net expense (benefit)	(5)	2	0	18
Restructuring net charges (credits)	83	1	93	5
	2,605	2,330	4,894	4,303
Operating income (loss)	819	520	1,740	1,195
Other income (expense):
Interest expense	(90)	(77)	(172)	(146)
Other, net	213	(23)	179	(21)
Income (loss) before income taxes	941	420	1,746	1,028
Income tax expense (benefit)	146	98	279	213
Net income (loss)	795	322	1,467	815
Net income (loss) attributable to noncontrolling interests	(2)	(2)	(4)	(4)
Net income (loss) attributable to Boston Scientific common stockholders	$797	$324	$1,471	$819
Net income (loss) per common share — basic	$0.54	$0.22	$0.99	$0.56
Net income (loss) per common share — diluted	$0.53	$0.22	$0.98	$0.55
Weighted-average shares outstanding
Basic	1,479.9	1,470.6	1,478.5	1,469.5
Diluted	1,493.5	1,484.2	1,493.3	1,483.0

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.